Protocol Ledger

NCT03354273 · Phase III · COMPLETED

An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz (18F) Injection PET MPI in the Detection of Coronary Artery Disease (CAD)

Interventional Phase III clinical trial protocol NCT03354273 sponsored by GE Healthcare in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-06-05 Enrollment: 730 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03354273
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)730 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03354273
Protocol FieldVerified Registry Value
NCT IdentifierNCT03354273
Consolidated Lead SponsorGE Healthcare
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment730 participants (ACTUAL)
Registered Start Date2018-06-05
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI